Abstract Purpose of Review Seven years after TDF/FTC was approved for pre-exposure
prophylaxis to reduce risks of HIV infection, there have been large increases in the number …

In 2012, the US FDA approved the first drug for use as HIV Pre-Exposure Prophylaxis
(PrEP), which is nearly 99% effective when taken as prescribed. Although the manifest …

Abstract Purpose Pre-exposure prophylaxis (PrEP) with oral emtricitibine/tenofovir disoproxil
fumarate (TDF/FTC) reduces the risk of HIV infection by> 90% when taken as prescribed …

Summary Background Pre-exposure prophylaxis (PrEP) has shown high efficacy in clinical
trials, but few observational studies have confirmed its effectiveness when prescribed in real …

Background Young men who have sex with men are among the most vulnerable to human
immunodeficiency virus (HIV) infection. Although preexposure prophylaxis (PrEP) has …

Clinical trials have demonstrated that preexposure prophylaxis (PrEP) protects against HIV
infection; yet, even with its approval by the Food and Drug Administration (FDA) in 2012 …

Introduction While bio‐behavioural interventions (BIs) for sexually transmitted infections
(STIs) and HIV prevention have shown their effectiveness (eg treatment for syphilis, HPV …

Introduction Persistence on preexposure prophylaxis for HIV prevention (PrEP) medication
has rarely been reported for periods greater than one year, or in real‐world settings. This …

Men who have sex with men (MSM) in the United States are at disproportionate risk for HIV.
Once-daily pre-exposure prophylaxis (PrEP) for HIV prevention is a highly effective method …

When used appropriately, pre-exposure prophylaxis (PrEP) substantially reduces the risk of
HIV acquisition. Early implementation outcomes often suggest poor PrEP adherence and …